StockMarketWire.com - Hemogenyx Pharmaceuticals said it had filed a patent covering new methods to transplant bone marrow and treat blood cancers.
The new patent covered a method of application of bi-specific antibodies (CDX) for conditioning patients for bone marrow transplantation and composition matter (sequences) of newly-discovered monoclonal antibodies against a target protein expressed on the surface of hematopoietic stem cells/hematopoietic progenitors and a number of leukemias, such as acute myeloid leukemia, the company said.
The antibody being developed, CDX, should, if successful, provide a new, effective and safe method of conditioning patients for bone marrow transplants, and had the potential to be a superior pharmaceutical for the treatment of blood cancers, for which survival rates are currently very poor,' the company said.
'Filing this patent is an important development and further solidifies Hemogenyx's leadership position in the development of new methods of bone marrow transplantation and treatments for blood cancers such as AML, acute lymphoblastic leukemia and possibly others,' it added.
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.